Shanghai Pharmaceuticals Financials
| SHPMY Stock | USD 7.88 0.32 3.90% |
Shanghai |
Understanding current and past Shanghai Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Shanghai Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Shanghai Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Shanghai Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Shanghai Pharmaceuticals Holding. Check Shanghai Pharmaceuticals' Beneish M Score to see the likelihood of Shanghai Pharmaceuticals' management manipulating its earnings.
Shanghai Pharmaceuticals Stock Summary
Shanghai Pharmaceuticals competes with McKesson, Cardinal Health, Henry Schein, Patterson Companies, and Owens Minor. Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company, researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in the Peoples Republic of China. Shanghai Pharmaceuticals Holding Co., Ltd. is a subsidiary of Shanghai Pharmaceutical Co., Ltd. Shanghai Pharmaceuticals operates under Medical Distribution classification in the United States and is traded on OTC Exchange. It employs 46577 people.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| ISIN | US81943R1005 |
| Business Address | Shanghai Pharmaceutical Building, |
| Sector | Healthcare |
| Industry | Medical Distribution |
| Benchmark | Dow Jones Industrial |
| Website | www.sphchina.com |
| Phone | 86 21 6373 0908 |
| Currency | USD - US Dollar |
Shanghai Pharmaceuticals Key Financial Ratios
Shanghai Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from Shanghai Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of Shanghai Pharmaceuticals over time and compare it to other companies across industries.| Return On Equity | 0.1 | |||
| Return On Asset | 0.0281 | |||
| Beta | 0.33 | |||
| Z Score | 1.6 | |||
| Last Dividend Paid | 0.42 |
Shanghai Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Shanghai Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Shanghai Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Shanghai Pharmaceuticals competition to find correlations between indicators driving Shanghai Pharmaceuticals's intrinsic value. More Info.Shanghai Pharmaceuticals Holding is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers reporting about 0.27 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Shanghai Pharmaceuticals Holding is roughly 3.64 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Shanghai Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Shanghai Pharmaceuticals' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Shanghai Pharmaceuticals Systematic Risk
Shanghai Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Shanghai Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Shanghai Pharmaceuticals correlated with the market. If Beta is less than 0 Shanghai Pharmaceuticals generally moves in the opposite direction as compared to the market. If Shanghai Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Shanghai Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Shanghai Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Shanghai Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Shanghai Pharmaceuticals November 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Shanghai Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Shanghai Pharmaceuticals Holding. We use our internally-developed statistical techniques to arrive at the intrinsic value of Shanghai Pharmaceuticals Holding based on widely used predictive technical indicators. In general, we focus on analyzing Shanghai Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Shanghai Pharmaceuticals's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.63 | |||
| Information Ratio | 0.0239 | |||
| Maximum Drawdown | 34.91 | |||
| Value At Risk | (6.87) | |||
| Potential Upside | 9.21 |
Additional Tools for Shanghai Pink Sheet Analysis
When running Shanghai Pharmaceuticals' price analysis, check to measure Shanghai Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Shanghai Pharmaceuticals is operating at the current time. Most of Shanghai Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Shanghai Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Shanghai Pharmaceuticals' price. Additionally, you may evaluate how the addition of Shanghai Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.